May, 17 2021 neurocare and MAG & More are joining forces

neu­ro­care and MAG & More are very pleased to announce the inte­gra­tion of MAG & More into theneu­ro­care group. MAG & More is a Ger­man based leader in the field of repet­i­tive tran­scra­nial­mag­netic stim­u­la­tion (rTMS) improv­ing the qual­ity of liv­ing for peo­ple suf­fer­ing from depression.rTMS assisted ther­apy is evi­dence based and reim­bursed in a grow­ing num­ber of coun­tries, such asthe US, Japan, Aus­tralia and Euro­pean key mar­kets. As well as depres­sion, rTMS is applied for anin­creas­ing num­ber of clin­i­cal indi­ca­tions such as obses­sive com­pul­sive dis­or­ders and pain. “This is akey step in strength­en­ing neurocare’s lead­ing Dig­i­tal Ther­a­peu­tics (DTx) plat­form and MAG & More’sgeographical cov­er­age is an excel­lent com­ple­ment to our own global foot­print” said Alexan­der­Zo­bel, COO Dig­i­tal Ther­a­peu­tics and Group CFO at neurocare.
By join­ing forces, both neu­ro­care and MAG & More will be stronger and more innovative.

Ker­stin­Häringer, Founder and CEO of MAG & More, is excited about the com­mon future: “I truly believe that­neu­ro­care and MAG & More make a per­fect match and I am much look­ing for­ward to shape the­fu­ture in men­tal health on a larger scale. neurocare’s holis­tic approach and their DTx plat­for­menable ther­a­pists to deliver best prac­tice by per­son­al­iz­ing ther­apy includ­ing the use of rTMS.”

Tom Mechter­sheimer, Founder and CEO of neu­ro­care, said: ”We warmly wel­come Ker­stin and herteam with their proud his­tory of devel­op­ing and mar­ket­ing high qual­ity tech­nol­ogy. We are look­ing­for­ward to dri­ving future inno­va­tions such as inte­grat­ing our novel neu­ro­car­diac-guided nav­i­ga­tion­sys­tem for rTMS within our DTx platform”.

About neurocare

www.neurocaregroup.com

neu­ro­care is inno­vat­ing men­tal health and per­for­mance and devel­oped a dig­i­tal ther­a­peu­tics (DTx) plat­form empow­er­ing clin­i­cians to deliver best prac­tice. Fol­low­ing a detailed assess­ment, clin­i­cians develop per­son­alised ther­apy plans that lead to best evi­dence-based out­comes. neurocare’s objec­tive and mea­sur­able approach is based on our brain’s nat­ural abil­ity to learn (neu­ro­plas­tic­ity) adding tech­nol­ogy to enhance that learn­ing and the care deliv­ery. Since this approach enables indi­vid­u­als to regain their sel­f­reg­u­la­tion it is a sus­tain­able solu­tion with very few side effects and sig­nif­i­cantly more than symp­tom management.

About MAG & More

www.magandmore.com

MAG & More is a med­ical device com­pany, design­ing, devel­op­ing and sup­ply­ing tran­scra­nial mag­netic stim­u­la­tion (TMS) sys­tems to pro­fes­sional health­care providers. Over 20 years ago their pio­neer­ing work  started by lis­ten­ing to and under­stand­ing early TMS researchers. Today their prod­uct range fits the needs of inno­v­a­tive researchers and clin­i­cians offer­ing evi­dence-based ben­e­fit of TMS for peo­ple suf­fer­ing from var­i­ous neu­ro­log­i­cal and psy­chi­atric ill­nesses. MAG & More’s focus lies on cre­at­ing inno­v­a­tive prod­ucts which ful­fil the high­est qual­ity stan­dards. Cor­re­spond­ing sup­port and train­ing pack­ages offer the right solu­tion for indi­vid­ual cus­tomer require­ments. A highly moti­vated team with a great deal of expe­ri­ence and an excel­lent team spirit are essen­tial to meet the needs of inter­na­tional customers.